Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.

Villeroy & Boch Aktie 352629 / DE0007657231

23.10.2025 08:00:14

EQS-News: Villeroy & Boch holds its own in a challenging market environment

EQS-News: Villeroy & Boch AG / Key word(s): Quarter Results
Villeroy & Boch holds its own in a challenging market environment

23.10.2025 / 08:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


 

Press Release

Mettlach, 23 October 2025

 

Villeroy & Boch holds its own in a challenging market environment

Revenue up 6.7% year-on-year to €1,075.2 million

In the current challenging market environment, the Villeroy & Boch Group recorded growth effects in the first nine months of the 2025 financial year as a result of the Ideal Standard acquisition. Despite general restraint in consumer spending and investment, the Group was able to increase sales by 6.7% to €1,075.2 million. Operating EBIT rose to €65.1 million, slightly above the previous year's level. Driven by the strategic realignment of the Group, growth was particularly strong in the EMEA region (Europe, Middle East, Africa) and in the fittings and shower systems business.

 

Satisfactory development despite weak global economy

The first nine months of the financial year were marked by a difficult global economic environment. In the Bathroom & Wellness division, the ongoing decline in the European residential construction sector, coupled with restrained investment – including in renovations – had a significant impact on business development.

“Against the backdrop of the current global economic situation and the associated restraint in consumer spending and investment, which is particularly affecting key growth markets for us such as China and the eurozone, we performed well in the market in the first nine months,” summarises CEO Gabi Schupp. “The positive response to our innovations in both business segments and the further internationalisation of our business are the result of our strategic realignment following the acquisition.”

 

EMEA region as growth driver for Bathroom & Wellness

In the first nine months of the 2025 financial year, the Bathroom & Wellness division increased its sales by 8.3% to €865.6 million due to acquisitions. The two strategic business areas – fittings and shower systems with a growth of €37.9 million, and sanitary ceramics and kitchens with an increase of €21.7 million – made a decisive contribution to this. The new ALU+ and Antao products and the i.life and Architectura collections were well received by the market. From a regional perspective, EMEA (Europe, Middle East, Africa) recorded strong growth of 13.4%, while the Asia-Pacific and Americas regions saw a decline in sales of 26.9%. Overall, the Bathroom & Wellness division succeeded in achieving operating EBIT of €52.5 million in the third quarter of 2025, in line with the previous year.

 

Dining & Lifestyle slightly above previous year's level

The Dining & Lifestyle division generated sales of €207.6 million in the first nine months of the 2025 financial year. It is particularly pleasing that sales in the pure product business, excluding licensing income, increased by 2.0% to €207.0 million. Particularly strong growth was achieved in the business with stationary retail partners (+11.0%) and in the project business for upscale hotels and restaurants (+8.9%). The Dining & Lifestyle division closed with an operating profit (EBIT) of €12.6 million, up 3.3% on the previous year.

 

Outlook for the full year 2025

The market environment remains highly uncertain. As a result of the continued slow economic recovery in the core markets, the Management Board of Villeroy & Boch AG is adjusting its forecast for the 2025 financial year: consolidated sales are expected to increase in the low single-digit percentage range, while operating EBIT and rolling operating return on net assets are expected to be slightly below the previous year's figures. Investments in property, plant and equipment and intangible assets are expected to remain slightly below the previous year.

 

Please find the complete Report as a PDF-file for download here:

http://www.villeroyboch-group.com/en/investor-relations/publikationen.html

 

 

Contact:

Melanie Schnitzler                                                   Anabell Westrich

Head of Corporate Communications                      Corporate Communications DACH

Tel: +49 (0) 151 / 23 54 75 55                                 Tel: +49 (0)6864 81-1338  

E-mail: schnitzler.melanie@villeroy-boch.com       E-mail: westrich.anabell@villeroy-boch.com



23.10.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


Language: English
Company: Villeroy & Boch AG
Saaruferstrasse 1-3
66693 Mettlach
Germany
Phone: +49 (0)6864 81-0
E-mail: information@villeroy-boch.com
Internet: www.villeroy-boch.de
ISIN: DE0007657231, DE0007657207
WKN: 765723
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2217200

 
End of News EQS News Service

2217200  23.10.2025 CET/CEST

Analysen zu Villeroy & Boch AG

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
Zu diesem Datensatz liegen uns leider keine Daten vor.
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

Abnehmspritzen – Ist der Hype vorbei? – mit Tim Schäfer

Ist der Hype um Abnehmspritzen wie bei Novo Nordisk und Eli Lilly vorbei – oder stehen wir erst am Anfang einer langfristigen Revolution im Gesundheitswesen? 💉📉

Im heutigen Gespräch mit Tim Schäfer @TimSchaeferMedia sprechen wir über die spannendsten Pharmawerte 2025. Neben den Abnehmspritzen blicken wir auch auf klassische Pharma-Giganten wie Pfizer, Johnson & Johnson, Roche, Novartis, AstraZeneca und GSK. Tim analysiert Übertreibungen, Rücksetzer und langfristige Chancen für Buy-and-Hold-Strategien – mit Fokus auf Dividende, KGV und Krisenresistenz.

💬 Was ist vom Abnehmtrend langfristig zu halten?
💬 Welche Pharma-Aktien sind aktuell unterbewertet?
💬 Was spricht für konservative Dividendenwerte im Gesundheitssektor?

👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/

Abnehmspritzen – Ist der Hype vorbei? – Wall Street Live mit Tim Schäfer

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 12’777.17 19.37 BWDSCU
Short 13’049.67 13.82 B7ZS2U
Short 13’525.87 8.98 B9GSAU
SMI-Kurs: 12’298.35 07.11.2025 17:31:28
Long 11’775.03 20.00 SIXBJU
Long 11’517.06 13.90 BBWS3U
Long 10’994.16 8.88 S2EBLU
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com